Loss of p53 Induces Tumorigenesis in p21-Deficient Mesenchymal Stem Cells  by Rodriguez, Rene et al.
Loss of p53 Induces
Tumorigenesis in p21-Deficient
Mesenchymal Stem Cells1,2
Rene Rodriguez*, Ruth Rubio*, Manuel Masip*,
Purificación Catalina*, Ana Nieto*,
Teresa de la Cueva*, Mar Arriero†,
Nuria San Martin†, Ernesto de la Cueva‡,
Dimitrios Balomenos§, Pablo Menendez*
and Javier García-Castro*
*Andalusian Stem Cell Bank (BACM)/University of
Granada, 18100 Granada, Spain; †Hospital Infantil Niño
Jesús, 28009 Madrid, Spain; ‡Cancer Research UK
Cambridge Research Institute, Cambridge CB2 0RE,
UK; §Centro Nacional de Biotecnología/Consejo
Superior de Investigaciones Cientificas (CSIC),
28049 Madrid, Spain
Abstract
There is growing evidence about the role of mesenchymal stem cells (MSCs) as cancer stem cells in many sarcomas.
Nevertheless, little is still known about the cellular and molecular mechanisms underlying MSCs transformation. We
aimed at investigating the role of p53 and p21, two important regulators of the cell cycle progression and apoptosis
normally involved in protection against tumorigenesis. Mesenchymal stem cells from wild-type, p21−/−p53+/+, and
p21−/−p53+/−mice were cultured in vitro and analyzed for the appearance of tumoral transformation properties after
low, medium, and high number of passages both in vitro and in vivo.Wild-type or p21−/−p53+/+ MSCs did not show
any sign of tumoral transformation. Indeed, after short-term in vitro culture, wild-typeMSCs became senescent, and
p21−/−p53+/+ MSCs showed an elevated spontaneous apoptosis rate. Conversely, MSCs carrying a mutation in one
allele of the p53 gene (p21−/−p53+/− MSCs) completely lost p53 expression after in vitro long-term culture. Loss of
p53 was accompanied by a significant increase in the growth rate, gain of karyotypic instability, loss of p16 expres-
sion, and lack of senescence response. Finally, these cells were able to form fibrosarcomas partially differentiated
into different mesenchymal lineages when injected in immunodeficient mice both after subcutaneous and intra-
femoral injection. These findings show that MSCs are very sensitive to mutations in genes involved in cell cycle
control and that these deficiencies can be at the origin of some mesodermic tumors.
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Introduction
The cyclin-dependent kinase (CDK) inhibitor p21Cip1/Waf1 (here-
after referred to as p21) is regulated by both p53-dependent and
-independent mechanisms on cellular stress, and the induction of
p21 may cause cell cycle arrest [1,2]. In addition to the loss of cell
cycle checkpoints, p21 deficiency commonly results in the lack of
both replicative and DNA damage–induced senescence [3,4] and
the increase of apoptosis after several stresses [5,6].
Unlike p53-deficient (p53−/−) mice, p21-deficient (p21−/−) mice
are resistant to early onset of tumorigenesis [7], although they de-
velop spontaneous tumors at an average age of 16 months. Remark-
ably, half of these tumors long-term developed by p21−/− mice display
a mesoderm origin (i.e., histiocytic sarcomas) [8]. Moreover, p21 de-
ficiency was shown to facilitate the susceptibility to sarcomas in p53+/−
and p53−/− mice [9]. Mouse embryonic fibroblasts (MEFs) derived
from p21−/− mice show a greater capacity to grow at late passages
compared with wild-type MEFs [7]. Similarly, p21 knockdown in
human fibroblasts allows cells to bypass senescence, although even-
tually, they enter a nonproliferative crisis state [3,10].
The consequences of p21 deficiency in adult stem cells have been
studied in hematopoietic stem cells (HSCs), neural stem cells, and
endothelial progenitor cells. In these cell types, p21 seems to control
their development and proliferation. p21−/− mice have more HSCs
than normal mice and fewer stem cells are in a quiescent state
[11]. Similar to HSCs, p21 contributes to the relative quiescence
of adult neural stem cells and the loss of p21 lead to the exhaustion
of their self-renewal capacity [12]. Endothelial progenitor cells num-
ber and their clonal expansion capacity are also elevated in p21−/−
mice compared with wild-type counterparts [13].
Studies in mesenchymal stem cells (MSCs) show that the overex-
pression of p21 protect them from programmed cell death induced
by low-density culture [14] and that there was an age-dependent de-
crease in the proliferation of MSCs associated with an up-regulation
of p21 [15]. In addition, p53, the better known activator of p21, has
also been reported to be mutated in a model of spontaneously trans-
formed MSCs, which recapitulated the naturally occurring fibrosar-
comas observed in aged mice [16]. However, there is no information
about the effects of p21 deficiency in MSCs.
Previous reports suggest that MSCs could behave as cancer stem
cells of certain sarcomas [17–21] and that their in vitro transforma-
tion would also generate both sarcomas [16,22–24] and carcinomas
[25,26]. Little is still known, however, about the cellular and molec-
ular mechanisms underlying MSCs transformation. The process of
MSCs transformation has been associated to the accumulation of
chromosome instability (CIN) [22–24] and high resistance to apop-
tosis [27], suggesting the relevance of an accurate cell cycle control in
MSCs. In fact, alterations in cell cycle regulators such as p16INK4A,
p53, and CDK-1, CDK-2, and CDK-6 [21,23,28] have been de-
tected in transformed MSCs.
On the basis of the relation between p21 deficiency and sarcoma-
genesis and in the ability of transformed MSCs to generate sarcomas,
we aimed to study the role of p21 and p53 during in vitro culture of
murine MSCs (mMSCs). We have derived and grown MSCs from
p21−/− and p21−/−p53+/− mice. We found that p21−/− MSCs grow
with similar characteristics to that of wild-type MSCs, except for a
greater apoptotic rate, and that these cells were not tumorigenic.
Strikingly, on the introduction of a mutation in one allele of p53
gene generating p21−/−p53+/− MSCs, we observed a complete loss
of p53 function after continuous in vitro culture associated with a
malignant phenotype as shown by the ability of these cells to form
sarcomas in immunodeficient mice.
Materials and Methods
Obtaining and In Vitro Culture of Mouse MSCs
p21−/− and p21−/−p53+/− mice on a C57BL/6J background have
been previously described and characterized [9,29]. Mesenchymal
stem cells were derived from adipose tissue. The tissue was cut into
small pieces and disaggregated for 2 hours, with the digestion me-
dium consisting of Dulbecco’s modified Eagle’s medium (Gibco,
Carlsbad, CA) with 1 mg/ml collagenase A (Roche, Basel, Switzerland).
The sample was centrifuged, filtered through 40-μm nylon filter
(Becton Dickinson, Franklin Lakes, NJ), seeded at a density of 1.6 ×
105 cells/cm2 in flasks with MesenCult for mouse cells medium and
MSC supplements (Stem Cell Technologies, Vancouver, Canada),
and incubated at 37°C in a 5% humidified CO2 atmosphere. After
24 hours, nonadherent cells were discarded, and fresh medium was
added. When cell culture achieved more than 90% of density, adherent
cells were trypsinized (0.25% trypsin; Sigma, St. Louis, MO), washed,
and replated at a concentration of 4 × 103 cells/cm2.
Flow Cytometry Analysis of MSCs
The immunophenotype of cultured MSCs was analyzed by flow
cytometry. Cells were trypsinized, washed, and suspended in PBS
with 1% bovine serum albumin (Sigma). A total of 2 × 105 cells were
incubated in the dark for 30 minutes with fluorochrome-conjugated
monoclonal antibodies (Sca-1, CD11b, CD34, CD45, CD44, and
CD29; BD Biosciences, San Jose, CA), washed, and analyzed in a
FACSCanto II cytometer (BD Biosciences).
Differentiation Studies of MSCs
Mesenchymal stem cells were plated at 5 × 103 cells/cm2 in
MesenCult medium and were allowed to adhere for 24 hours. Culture
medium was then replaced with specific differentiation inductive me-
dia. For adipogenic differentiation, cells were cultured in Adipogenic
MSCs Differentiation BulletKit (Lonza, Basel, Switzerland) for
2 weeks. Differentiated cell cultures were stained with Oil Red O
(Amresco, Solon, OH). For osteogenic differentiation, cells were cul-
tured inOsteogenicMSCsDifferentiationBulletKit (Lonza) for 2weeks.
Differentiated cell cultures were stained with Alizarin Red S (Sigma).
In Vitro Cell Growth Analysis
Cell cultures were checked daily for changes in growth rates and
morphology. Growth curves were performed by assessing the cell
number in triplicate MSC cultures for 8 days. For colony-forming
assays, cells were plated in triplicate at low density (2000 cells/
100-mm dish). Cells were allowed to grow for 10 to 15 days before
staining them with 0.5% crystal violet (Sigma)/25% methanol. Only
colonies of >50 cells were scored.
Karyotypic Analysis
Cells were cultured in medium supplemented with 0.1 mg/ml col-
cemid (Sigma) for 3 to 4 hours, washed with PBS, and trypsinized.
The subsequent pellet was carefully resuspended in hypotonic solu-
tion of KCl (0.075 M), incubated for 20 minutes at 37°C, spun
down, and fixed in Carnoy’s solution (methanol/acetic acid ratio,
3:1). The fixing procedure was repeated three times, and the pellet
was finally resuspended in 1 ml of fixative. Cells were then dropped
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on glass slides, and the chromosomes were visualized by using mod-
ified Wright’s staining. Metaphases were analyzed using conventional
microscope (Leica DM 5500B, Solms, Germany), and the karyotypes
were prepared using IKAROS software (Metasystems, North Royalton,
OH). Fifty metaphases were analyzed for each culture.
Cell Cycle Analysis
Cell cycle analysis was carried out by flow cytometry after propi-
dium iodide staining of 70% ethanol-fixed cells as previously de-
scribed [6].
Detection of Apoptosis
Apoptotic cells were assessed by flow cytometry using PE–Annexin
V according to the manufacturer’s instructions (BD Biosciences).
Senescence-Associated β-Galactosidase Staining
After the indicated treatments, cells were fixed and incubated over-
night with X-gal solution (pH 6.0) as previously described [10].
In Vivo Tumorigenesis Assay
Nonobese diabetic/severe combined immunodeficient NOD.Cg-
Prkdc scid IL2rg tm1Wjl/SzJ (NOD/SCID-IL2R−/−) mice were obtained
from The Jackson Laboratory (Bar Harbor, ME). All mice were
housed under specific pathogen-free conditions, fed ad libitum accord-
ing to Animal Facilities guidelines, and used at 8 to 12 weeks of
age. All protocols involving mice were approved by the Institutional
Animal Care and Use Committee. Female NOD/SCID-IL2R−/− mice
were infused subcutaneously with 3 × 106 cells. According to the
UKCCCR guidelines for the welfare of animals in experimental neo-
plasia, animals were killed when their tumors reached approximately
a diameter of 10 mm or 5 months after inoculation. Tumors and
organs extracted for further analyses. In some experiments, a fraction
of tumors was incubated in culture medium containing 1 mg/ml
collagenase A for 3 hours. Then, disaggregated samples were cen-
trifuged, filtered through 40-μm nylon filter, and seeded in culture
as described above to reestablish ex vivo culture of tumor cells.
Histologic Analysis
Tumor samples were fixed in 4% buffered formalin, embedded in
paraffin wax, cut into 4 μm sections, and stained with hematoxy-
lin and eosin. The histologic diagnosis was performed following
the criteria of the World Health Organization described by Ernst
et al. [30] taking in account the infiltrative growth, cellular pleomor-
phism, and cellular malignancy. Immunohistochemical staining was
carried out using the ABC Vectasain Elite Kit (Vector Laboratories,
Burlingame, CA) according to manufacturer’s instructions and counter-
stained with hematoxylin. After a previous unmasking antigen with
heat and blocking unspecific protein with MOM kit (Vector Labo-
ratories), the primary antibody antihuman β-tubulin III (Chemicon,
Billerica, MA) was incubated at a dilution 1:100 for 1 hour at room
temperature. Immunoreactivity was observed with 3-3′ diaminobenzi-
dine tretrachloride (Vector Laboratories).
Western Blot Analysis
Whole-cell extracts were prepared after treatment with or with-
out 0.5 μM camptothecin (CPT; Sigma) for 24 hours as described
previously [31], resolved on 10% SDS-PAGE gels, and blotted onto
nitrocellulose (BioRad, Hercules, CA). Proteins were detected with
the enhanced chemiluminescence detection system (Amersham,
Buckinghamshire, England) using anti-p21 (sc-6246), anti-p53 (sc-
6243), anti-p16 (sc-74401), and anti–c-myc (sc-41) from Santa Cruz
Biotechnology, Santa Cruz, CA; anti–phospho-p53 (Ser15) (PC386)
and anti-p19 (PC435) from Calbiochem, Dormstadt, Germany; or
anti–β-actin (A1978) from Sigma.
Results
Characterization of p21−/−p53+/+ and p21−/−p53+/−
Mouse MSCs
Mesenchymal stem cells from wild-type, p21−/−p53+/+, and p21−/−
p53+/− mice were maintained in culture for short-term (ST; pas-
sages 3-15), medium term (MT; passages 16-35) or long-term (LT;
passages 36-60) periods. During ST in vitro culture, cells from all
genotypes showed a typical fibroblast-like morphology (Figure 1A).
However, after continuous culture, p21−/−p53+/− (MT and LT) MSCs
changed from an elongated spindle shape to a small, compact mor-
phology (Figures 1A and 2A). All these cell types showed their
capacity to differentiate to adipocytes and osteocytes after specific
stimulation as usual in MSCs (Figure 1A). Nevertheless, the p21−/−
p53+/− (LT) MSCs showed poorer differentiation to the adipogenic
lineage. After ST culture, all MSCs expressed the cell surface antigens
Sca-1, CD44, and CD29 and lacked expression of the hematopoietic
markers CD45, CD14, and CD11b, therefore displaying a common
mouse-MSC phenotype [32,33] (Figure 1B). Intriguingly, after LT
culture, p21−/−p53+/− MSCs had almost completely lost the expres-
sion of Sca-1, although the rest of the markers remain in a similar
level of expression. Taken together, the changes observed in p21−/−
p53+/− MSCs after long-term culture suggest a different in vitro ho-
meostasis behavior.
In Vitro Immortalization of p21−/−p53+/− MSCs After
Extensive Cell Culture
Ongoing experimental evidence suggests that normal MSCs, like
most of primary cell cultures, enter senescence on several passages
in vitro [34]. Here, after 10 to 15 passages, wild-type MSCs showed
a pronounced increase in size with prominent and enlarged nuclei
characteristic of senescent cells. In fact, the entire cell population
stained for senescence-associated β-galactosidase activity (SA-β-gal;
Figure 2A). After identical number of passages, p21−/−p53+/+ MSCs
showed a significantly lower level of senescence cells, although in
these cultures, a high proportion of smaller, rounded, and partially
detached apoptotic cells were detected (Figure 2A). Almost half of
the p21−/−p53+/+ MSCs undergoes spontaneous apoptotic response
as quantified by Annexin V binding (Figure 2B). As a consequence
of these antiproliferative effects (senescence and/or apoptosis), cul-
tures of wild-type and p21−/−p53+/+ MSCs did not progress any
further. Conversely, p21−/−p53+/− MSCs did not undergo either se-
nescence or apoptosis. Opposite to these effects, after 17 to 22 pas-
sages, a colony showing a small, rounded morphology arose in these
cultures (Figure 2A). This cell population showed a growth rate
much higher than the normal spindle-shaped cells and completely
took over the entire culture after a few passages. As a consequence,
p21−/−p53+/− (MT) MSCs displayed an immortalized/transformed
phenotype that includes the loss of contact inhibition, a growth rate
much higher than wild-type, p21−/−p53+/+ or p21−/−p53+/− (ST)
MSCs (Figure 2C ) as a result of a higher mitotic index (data not
shown), and the gain of clonogenic capacity (Figure 2D).
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Karyotypic analysis showed moderate levels of chromosomal in-
stability in wild-type and p21−/−p53+/+ MSCs as expected for pri-
mary cultures of mouse cells. Nevertheless, relevant differences in
the level of instability have been found. Thus, approximately 50%
to 60% of metaphases from wild-type (ST) and p21−/−p53+/+ (ST)
MSCs cultures showed normal karyotypes. The rest of the meta-
phases gained chromosomes, showing most of them a karyotype
with 41 to 70 chromosomes (Figure W1, A and B). Conversely,
cultures from p21−/−p53+/− (ST) showed a higher level of chromo-
somal instability, because virtually, the whole population had gained
extra chromosomes, with 80% of them displaying karyotypes of
more than 70 chromosomes. After LT culture, these cells showed
a kind of adaptation to in vitro culture conditions and lost some
of the previously gained chromosomes (Figure W1, A and B). Cell
cycle analysis of these cells confirm that p21−/−p53+/− (ST) had
almost double DNA content than wild-type or p21−/−p53+/+ cells
and that p21−/−p53+/− (LT) presented an intermediate amount of
DNA content (Figure W1C ). Cell cycle profiles also revealed a
higher proportion of cells in S-phase in p21−/−p53+/− (LT; 23.20%)
compared with p21−/−p53+/− (ST; 17.89%) cells and especially to
Figure 1. MSCs characterization. (A) Morphology, Oil Red O staining (adipogenic differentiation), and Alizarin Red staining (osteogenic
differentiation) of the indicated MSCs. Original magnification, ×20. (B) Fluorescence-activated cell sorting analysis of MSC surface mar-
kers. Filled line, control isotype; empty line, cells incubated with the indicated antibody.
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wild-type (9.09%) and p21−/−p53+/+ (9.05%) cells according to their
growth rates.
Loss of p53 and p16 Expression in p21−/−p53+/− MSCs After
Long-term Cell Culture
To better understand the observed transformation of p21−/−p53+/−
after LT in vitro culture, we analyzed the expression of relevant cell
cycle regulators in control conditions or after a 24-hour treatment with
the topoisomerase I inhibitor CPT, which induces DNA damage in
the form of replication fork stress, as a control for the activation of
some of these proteins (Figure 3A). As expected, expression of p21
was completely absent in all of the p21−/− MSCs, whereas it was highly
expressed and further upregulated after CPT treatment in wild-type
cells. Conversely, expression of p53 was similar in wild-type and
p21−/−p53+/− (ST) cells and was slightly lower in p21−/−p53+/+ cells.
A strong activation (up-regulation and phosphorylation in serine 15)
of p53 was also observed after CPT treatment of these cells. More
importantly, the expression and activation of this protein were highly
abrogated in p21−/−p53+/− (MT) cells and completely disappeared in
p21−/−p53+/− (LT) MSCs.
We next analyzed the expression of the proteins codified by the
INK4A/ARF locus p16 and p19 whose altered expressions have been
reported in other models of transformed MSCs [23,35]. The expres-
sion pattern of p16 was similar to that observed for p53, showing a
high expression level in wild type, p21−/−p53+/+, and p21−/−p53+/−
(ST) cells, a great reduction of their levels in p21−/−p53+/− (MT), and
complete absence of expression in p21−/−p53+/− (LT) MSCs. Opposite
to p16, p19 was poorly expressed in wild-type and p21−/−p53+/+ cells
but highly expressed in p21−/−p53+/− independently of their time in
culture (Figure 3A).
Overexpression of c-myc is a common event associated with tu-
moral transformation of MSCs [22,23]. Compared with wild-type
Figure 2. p21−/−p53+/− MSCs were transformed after extensive in vitro culture. (A) Representative images of senescence-associated
β-galactosidase (SA-β-gal) assays of wild-type (passage 12), p21−/−p53+/+ (passage 11), and p21−/−p53+/+ (passage 20) MSCs. SA-β-
gal senescent-positive cells (black arrows), apoptotic cells (red arrows), and the outgrowth of a transformed population (blue arrow)
are indicated. Original magnification, ×20. (B) Annexin V binding assay of a culture of p21−/−p53+/+ (ST) cells. (C) Growth curves
of the indicated MSCs. (D) Representative plates of colony formation assays showing the gain of clonogenic capacity of p21−/−p53+/−
(LT) MSCs.
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cells, the expression of this oncogenic protein was virtually undetect-
able in p21−/−p53+/+ (ST) cells but upregulated in p21−/−p53+/− (ST)
and, in a lower degree, in p21−/−p53+/− (MT) cells (Figure 3B). In-
triguingly, c-myc levels decrease after LT culture of p21−/−p53+/−
MSCs to the levels of wild-type cells. This pattern of expression
agrees with previously published data, which suggest a role for c-myc
in senescence bypass during spontaneous tumoral transformation of
human MSCs [23,28].
Lack of Serum Deprivation Induced Senescence in
p21−/−p53+/− (LT) Cells
The induction of replicative or DNA damage–induced senescence
constitutes one of the most important antitumoral barriers. In mam-
malian cells, senescence is dependent on functional p53/p21 and/or
p16 pathways [36], which are both compromised in p21−/−p53+/−
(LT) MSCs. To test the ability of wild-type, p21−/−p53+/−, (ST)
and p21−/−p53+/− (LT) MSCs to senesce, the cells were deprived of
serum for up to 6 days before being stained for SA-β-gal (Figure 4, A
and B). Control cultures of wild-type and p21−/−p53+/− (ST) showed
a basal level of senescence (approximately 20%). Serum deprivation
of these cells showed a similar time-dependent increase in the per-
centage of senescent cells, reaching a maximum of 80% after 6 days.
Conversely, p21−/−p53+/− (LT) cells did not stain at all for SA-β-gal
even after 6 days of being deprived of serum. However, during the
experiment, these cells became smaller, rounded, and highly re-
fringent, resembling apoptotic cells (Figure 4A). Annexin V binding
experiments were done to confirm this apoptotic effect (Figure 4C ).
Wild-type cells showed only a modest apoptotic induction of 20%
after 6 days of serum deprivation. Meanwhile, this apoptotic effect
increased up to 40% in p21−/−p53+/− (ST) MSCs and virtually af-
fected the whole population in p21−/−p53+/− (LT) MSCs after the
same period. These results stress the relevance of p53, p21, and p16
in the induction of senescence and suggest an important role of this
mechanism in the protection against tumoral transformation of MSCs.
Nevertheless, these results also suggest that agents that induce senes-
cence could be efficient apoptotic inducers in transformed MSCs
knocked down for p53/p21 and p16 pathways.
In Vivo Tumor Formation Potential of p21−/−p53+/− MSCs
To test the ability of p21−/−p53+/− MSCs to form tumors in vivo,
we introduced cells of the different studied genotypes into immuno-
deficient mice through subcutaneous injection. One hundred fifty
days after the inoculation of wild-type, p21−/−p53+/+, or p21−/−p53+/−
(ST) MSCs, no signs of illness or tumor formation were observed
in any mice (Table 1). In contrast, inoculation of p21−/−p53+/−
(MT) or p21−/−p53+/− (LT) cells originated tumors in all injected
mice (Figure 5). Eventually, tumors developed ulcers in the skin
when the diameter reached approximately 7 to 10 mm, and the mice
in these groups were killed. p21−/−p53+/− (MT) and p21−/−p53+/−
(LT) MSCs reached this point 105 and 74 days after inoculation,
respectively, evidencing the more aggressive phenotype of p21−/−
p53+/− (LT), which completely lacks p53 and p16. Anatomopatholo-
gical analysis classified tumors as fibrosarcomas, showing most cells
an elongated shape, anisocytosis, anisokaryosis, and an elevated mi-
totic index (Figure 5). Tumors obtained from p21−/−p53+/− (MT)
showed areas of adipose tissue differentiation, whereas tumors from
p21−/−p53+/− (LT) MSCs displayed not only adipose but also osteo-
cytic differentiation as well as signs of neural differentiation, as in-
dicated by β-tubulin III staining of cells residing inside nerve-like
structures (Figure 5). Moreover, small nodules of metastasis were
found in lungs from some mice (Figure 5).
In addition, we have also tested the ability of p21−/−p53+/+ and
p21−/−p53+/− (LT) MSCs to form tumors in vivo in an environment
characteristic of MSCs such as bone marrow. Thus, MSCs were in-
jected into the femurs of immunodeficient mice (Table 1). Again, no
tumors were observed from p21−/−p53+/+ MSCs. Conversely, all the
mice injected with p21−/−p53+/− (LT) MSCs developed fibrosarcomas
with some level of fat differentiation, present both inside the bone
marrow and infiltrated between the muscles surrounding the bone
(Figure 5). Altogether, these results confirm that p21 knockdown
per se is not enough to transform MSCs, but simultaneous and grad-
ual loss of p53 and p16 expression cooperate to induce an increas-
ingly aggressive tumorigenic phenotype.
Characterization of Cells Derived from p21−/−p53+/−
MSC-Induced Tumors
We next extracted and cultured cells from tumors derived from
p21−/−p53+/− (MT) (Tp21p53/MT) and from p21−/−p53+/− (LT)
cells (Tp21p53/LT). Cells from both tumors showed similar growth
properties compared with their parental MSCs, including morphol-
ogy (Figure 6A), absence of contact inhibition, elevated mitotic
index, and clonogenic capacity (data not shown). Tp21p53/MT
and LT cells were negative for CD45, CD14 and CD11b, positive
for CD44 and CD29 and weakly positive for Sca-1 (Figure 6B),
Figure 3. p53 and p16 are gradually lost after in vitro culture of
p21−/−p53+/− MSCs. Levels of p21, total p53, phospho-p53 (ser
15), p16, p19 (A) and c-myc (B) in the indicated MSCs treated or
not with 0.5 μM CPT for 24 hours. β-Actin levels are presented as a
loading control.
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similar to the parental MSCs. These cells showed a strong ability for
osteogenic differentiation together with a weak differentiation to
adipocytes (Figure 6A), similar to that reported for p53−/− MSCs
[37]. Indeed, both Tp21p53/MT and Tp21p53/LT cells did not
express p21 or p53 proteins (Figure 6C ). Like the parental MSCs,
Tp21p53/MT showed a reduced expression of p16, which was com-
pletely absent in Tp21p53/LT cells, whereas the p19 levels were
highly upregulated in both type of cells compared with wild-type
MSCs. Likewise, c-myc levels were similar in wild-type and both
tumor-derived cells, following the pattern of expression of their pa-
rental MSCs (Figure 6D).
Tumor-derived cells also showed a great increase in the number
of chromosomes, presenting a medium of 63 chromosomes in
Tp21p53/MT and 75 in Tp21p53/LT cells (Figure W2A). The dif-
ferences in DNA content were also confirmed by cell cycle analysis
(Figure W2B). Percentage of cells in the S phase in tumor-derived
Table 1. In Vivo Tumor Formation Ability of p21−/− MSCs.
Subcutaneous Injection Intrafemoral Injection
Tumors/Mice Days to Tumor Development* Histologic Analysis Tumors/Mice Histologic Analysis
wild-type 0/5 NT† Normal — —
p21−/−p53+/+ 0/5 NT† Normal 0/4 Normal
p21−/−p53+/− ST 0/5 NT† Normal — —
p21−/−p53+/− MT 5/5 105 Fibrosarcoma + fat — —
p21−/−p53+/− LT 5/5 74 Fibrosarcoma + fat + bone + nerve 4/4 Fibrosarcoma + fat
*Average number of days needed to observe tumor ulceration and an approximate tumor diameter of 8 mm. Mice carrying tumors were killed at this point.
†NT, no tumors were detected. Mice were killed 150 days after injection.
Figure 4. Senescence induction after serum deprivation of p21−/−p53+/− MSCs. The indicated MSCs were deprived of serum for the
indicated days and analyzed for senescence-associated β-galactosidase (SA-β-gal) activity (A, representative images; original magnifi-
cation, ×20; B, mean and SD of three independent experiments) or for the Annexin V binding (C, percentage of Annexin V-positive
apoptotic cells is indicated).
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cells (22.07% for Tp21p53/MT cells and 23.81% for Tp21p53/LT
cells) was again similar to that observed in their parental MSCs. In
summary, the cells recovered from tumors showed a phenotype and
biological behavior similar to that observed in the parental trans-
formed MSCs, p21−/−p53+/− (MT) and p21−/−p53+/− (LT).
Discussion
p21 plays important roles in regulating key antitumoral bar-
riers such as cell cycle control, senescence, and apoptosis, and its defi-
ciency predisposes mice to spontaneous and induced tumorigenesis.
Most of these spontaneous tumors observed in p21 knockout mice
were sarcomas [8], and p21 deficiency also increased the percentage
of sarcomas in p53-deficient mice [9]. These data suggest a potential
link between p21 deficiency and sarcomagenesis. In addition, human
and mouse MSCs transformed after in vitro culture generated sar-
comas in vivo [21–24], and human MSCs have been proposed as
cancer stem cells for certain sarcomas [16–20]. Thus, we wanted
to test if p21-deficient MSCs could be transformed in vitro and form
sarcomas in vivo.
Our study suggests that p21 deficiency of is not enough for MSC
immortalization, even losing one allele of p53. However, serial cul-
tivation of p21−/−p53+/− mMSCs was accompanied of a total loss
of heterozygosity in p53 function. As a result, long-term cultured
p21−/−p53+/− mMSCs became immortalized and were able to induce
tumor formation into immunodeficient mice, according to the two-
hit model of tumorigenesis (see Figure W3 for a summary of the
transforming events observed in the MSCs cultures). Altogether,
we conclude that the deficiency of p21 and p53 would generate sar-
comas from MSCs.
According to our data, it has been reported that the loss of p21 ac-
celerated tumor onset in mice deficient for p53-induced apoptotic
function, and these tumors showed an increased CIN [38]. We found
a similar increase in CIN in p21−/−p53+/− MSCs even after a short
number of passages when p53 protein is still expressed and can be
phosphorylated after DNA damage, suggesting that p53 is haploinsuf-
ficient to maintain chromosomal stability in a p21−/− background.
Loss of heterozygosity has previously been reported after in vitro
culture of p21, p53, Rb, or p16 heterozygous human fibroblasts [39].
In this case, cells that lost heterozygosity for p21, p53, and Rb but
not for p16 were able to bypass senescence, although the extended life
span of these cells eventually terminated in a crisis state. Likewise,
fibroblast from patients with Li-Fraumeni syndrome (p53+/−) sponta-
neously lost the wild-type p53 allele and gained extended life span
[40]. Moreover, spontaneous immortalization of murine fibroblasts
is frequently associated with a mutation of p53 [41], and wild-type
and p21−/− MEF cultures acquire alterations in p53 [42]. In MSCs,
genetic changes, in particular, p53 mutations, occur after long-term
in vitro proliferation [21]. In our model, p21−/−p53+/− mMSCs, which
completely lost p53 expression, became not only immortalized but
also transformed, suggesting an important role for p21 in the preven-
tion of tumorigenesis in MSCs.
Loss of p21 also permits carcinogenesis in chronically damaged
epithelial cells despite having lost the p21 antiapoptotic functions
[43]. We have also noticed a higher apoptosis rate in p21−/− MSC
Figure 5. In vivo tumor formation ability of transformed p21−/−p53+/− MSCs. Hematoxylin and eosin staining (and β-tubulin III immu-
nohistochemistry for e) of tumors obtained after subcutaneous or intrafemoral injection of p21−/−p53+/− (MT) and p21−/−p53+/− (LT) as
indicated. Tumors generated after subcutaneous injection were mostly composed of elongated cells typical of fibrosarcomas (a, black
arrow) showing anisocytosis, anisokaryosis and an elevated mitotic index. These tumors also showed areas of adipose tissue differen-
tiation (b, c, white arrows), osteogenic differentiation (d, yellow arrow) and nerve-like structures showing positive staining for β-tubulin III
(e, blue arrow). Lungs infiltrated with p21−/−p53+/− transformed MSCs were observed in some mice (f). Tumors generated after intra-
femoral injection of p21−/−p53+/− (LT) MSCs showed the same fibrosarcoma morphology and were present both inside the bone mar-
row (g, see red arrow for tumor cells, white arrow for adipose differentiation, and green arrow for bone marrow) and infiltrated between
the muscle surrounding the bone (h, orange arrow). Original magnifications: all (except in b and f, ×10), ×4.
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cultures, and similar observations have been reported in other cell
types. Thus, p21−/− mice show a defect in the induction of p53-
mediated G1/S arrest in response to γ-radiation [7] but maintain
an intact apoptotic response [29]. In addition, irradiation-induced
thymic lymphomas in p21-null mice show a significantly higher level
of apoptosis compared with that in wild-type mice [8]. Moreover,
lymphocytes in the spleen of p21-deficient mice display a higher level
of constitutive apoptosis compared with wild-type mice [44].
Other alterations detected during the in vitro culture of p21−/−p53+/−
MSCs included the loss of p16 expression accompanied by a high
up-regulation of the related tumor-suppressor protein p19 and a
transient up-regulation of c-myc. p16 and p19 are encoded by over-
lapping reading frames in the same gene (INK4/ARF ), so p16 silenc-
ing is not due to the loss of this locus. In this regard, it has been
reported that p16 expression is closely associated with senescence of
human MSCs and could be silenced by DNA methylation during
in vitro expansion of these cells [45]. Repression of p16 expression
has also been reported in a case of spontaneous transformation of hu-
man MSCs [23,28]. Another study shows that the loss of p16 with
retention of p19 is enough to predispose mice to tumorigenesis [46].
Figure 6. Characterization of cell lines derived from p21−/−p53+/− MSCs-induced tumors. (A) Morphology, Oil Red O staining (adipo-
genic differentiation), and Alizarin Red staining (osteogenic differentiation) of the indicated tumor-derived cells. Original magnification,
×20. (B) Fluorescence-activated cell sorting analysis of MSCs surface markers. (C) Levels of p21, total p53, phospho-p53 (ser 15), p16,
and p19 in wild-type MSCs or tumor-derived cell lines treated or not with 0.5 μM CPT for 24 hours. β-Actin levels are presented as a
loading control. (D) c-myc levels in the indicated cells. Loading controls are the same as in (C).
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p19 regulates a route for p53 stabilization in response to aberrant
growth or oncogenic stresses [47]. We hypothesized that the high lev-
els of p19 observed could be due to an insufficient activation of p53 in
p53+/− and p53−/− MSCs in response to the high level of CIN and/or
the c-myc up-regulation observed after in vitro culture of these cells.
Activation of c-myc has been demonstrated as a very relevant event
in the transformation process of human MSCs [48], being commonly
upregulated in cases of transformation of human and mMSCs [22,23].
The transient up-regulation of c-myc in MSCs has been associated
with the bypass of cellular senescence [28].
In mammalian cells, senescence is initiated by one of these two
signaling pathways: p53/p21 and p16/Rb [36]. In human fibro-
blasts, it has been shown that the up-regulation of p21 is the primary
response-inducing cellular senescence, whereas the up-regulation of
p16 occurs weeks after the induction of cell cycle arrest [49]. In this
regard, the inactivation of p21 and INK4 pathways in a mouse
model strongly cooperates in suppressing cellular senescence [50].
Interestingly, this double mutant displays an increased incidence of
sarcomas compared with the single mutants. In our model, the loss of
p21, p53, and p16 suppresses not only replicative but also serum
deprivation–induced senescence. Intriguingly, p21−/−p53+/− (LT) cells
that do not senesce after 6 days of serum deprivation undergo a p53-
independent apoptotic cell death, suggesting that agents that induce
senescence could be efficient apoptotic inducers in transformed
MSCs deficient for p53/p21 and p16 pathways.
In summary, transformation of MSCs seems to be highly depen-
dent on alterations in the p21/p53 pathway. Our data indicate that
p21-deficiency itself is not sufficient to allow MSCs immortalization.
However, when the p21 deficiency is coupled to p53 deficiency, the
MSCs bypass senescence in vitro and generate tumors that resemble
typical mesenchymal sarcomas in vivo. Our study suggests the hy-
pothesis that MSCs might require few genetic alterations to undergo
transformation and may act as the cellular origin for sarcomas.
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Figure W1. Genetic instability in p21−/−p53+/−MSCs. (A) G-banded karyotypes representative of the indicated MSCs. (B) Percentages of
metaphases containing the indicated number of chromosomes. At least 50 metaphases of each MSC type were counted. (C) Cell cycle
analysis of the indicated MSCs. 2N DNA content peak according to the G1 population of wild-type MSCs and corresponding to 4N and
8N DNA content peaks are pointed.
Figure W3. Summary of transforming events in p21−/−p53+/− MSCs cultures.
Figure W2. Genetic instability in Tp21p53 tumor cells. (A) G-banded karyotypes representative of the indicated tumor cell lines. (B) Cell
cycle analysis. 2N DNA content peak according to the G1 population of wild-type MSCs and corresponding to 4N and 8N DNA content
peaks are pointed.
